There have been no open-market insider trades at Heron Therapeutics, Inc. in the last 12 months.
Looking at the quarterly pattern: No open-market insider buying or selling in the last full quarter. Insiders bought in 1 of the last 7 full quarters. Big money check: 162 institutions held HRTX as of Q2 2026, and more funds bought than sold.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Aug 12, 2025 | Rosen David Efraim | 10% Owner | Buy | 2,387,225 | $1.50 | $3.6M | SEC |
| Aug 12, 2025 | Morgan Adam | Director | Buy | 1,766,546 | $1.50 | $2.6M | SEC |
| Nov 21, 2023 | Forbes William P | Executive Officer | Buy | 25,000 | $1.09 | $27K | SEC |
| Nov 20, 2023 | Forbes William P | Executive Officer | Buy | 50,000 | $0.94 | $47K | SEC |
| Nov 17, 2023 | Collard Craig A | CEO | Buy | 150,000 | $0.92 | $138K | SEC |
| Nov 17, 2023 | Duarte Ira | CFO | Buy | 85,000 | $0.89 | $76K | SEC |
| Jul 25, 2023 | Morgan Adam | Director | Buy | 2,486,744 | $1.37 | $3.4M | SEC |
There were no open-market insider trades in HRTX in the last 12 months. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
162 investment managers reported holding HRTX in SEC Form 13F filings for Q2 2026.
No congressional trades in HRTX were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).